Biovian is delighted to announce the successful completion of a debt refinancing initiative and securing a new funding package with Eurazeo, a French investment company, to support GeneCity facility expansion. The package will be used …
Biovian, a leading biopharmaceutical CDMO from Finland, uncovers the stonemasonry work of its new manufacturing facility, GeneCity. Located in a growing technology hub at Turku, Kupittaa, the state-of-the-art facility houses a blend of cutting-edge equipment …
We invite you to explore the recent article “Next Level Biopharmaceuticals” featured in the Business Focus Magazine’s latest issue. Business Focus Magazine interviewed Biovian’s CEO and co-founder Antti Nieminen about Biovian’s growth story and position …
Biovian Oy, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, announces a major investment of over €50 million to expand its manufacturing facility in Turku, Finland. The new facility will cover an …
Viral contaminations are rare events in biopharmaceutical manufacturing, but regulatory agencies expect all biologics to undergo viral clearance testing to mitigate the risk of contamination [1, 2]. Therapies based on viral vectors have a small …
The article discusses the reasons behind the growing need for viral vectors and how Biovian, as a CDMO has taken actions to solve the manufacturing bottleneck. Antti Nieminen, CEO of Biovian: “The majority of Biovian’s customers …
Outsourcing as a business model within the Life Science-industry is growing year by year. Choosing the right contract development and manufacturing organization (CDMO) has become an important factor for the success of drug product development. …
The whys and the whats of GMP production of biopharmaceuticals. Why’d you have to go and make things so complicated? This chorus of the pop-rock song, Complicated, may reflect the thoughts of drug developers when …
The leading regional newspaper of of the Southwest Finland interviewed Knut Ringbom, the CEO of Biovian about the COVID-19 vaccine manufacturing possibilities. “Pandemic vaccine manufacturing is a hot topic. We have been contacted by European …
GEN, one of the biggest biotech magazines interviewed Biovian about the critical bottlenecks in Adeno-associated virus (AAV) Manufacturing. AAVs, gene therapy and manufacturing technologies are two of the “hottest” biotech areas in the industry right …